SequelSEC

Korsana Biosciences, Inc. CYCN

Pharmaceutical Preparations · CIK 0001755237 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.07M
Fiscal year ended 2025-12-31
Operating income
-$4.97M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Korsana Biosciences, Inc. (CYCN) reported revenue of $2.07M and net income of -$3.53M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Korsana Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Korsana Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$2.07M$2.00M$0$297.00K$3.94M$2.30M$4.51M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$4.97M-$3.63M-$12.95M-$18.54M-$55.20M-$81.26M-$125.04M
Net income-$3.53M-$3.06M-$5.26M-$44.08M-$51.65M-$77.80M-$123.01M
Research & development$959.00K$286.00K$1.52M$5.98M$37.64M$56.41M$95.14M
Weighted-average diluted sharesshares 3.18Mshares 2.52Mshares 2.34Mshares 2.17Mshares 39.14MUnavailableUnavailable
Pretax income-$3.53M-$3.06M-$5.26M-$44.08M-$51.65M-$122.41M-$122.41M
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$-1.11$-1.21$-2.25$-20.28$-1.32UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.09M$5.34M$8.13M$12.86M$20.62M$28.82M$34.40M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Korsana Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$3.24M$3.23M$7.57M$13.38M$53.96M$54.40M$94.90M
Total assets$9.98M$9.58M$13.37M$18.08M$59.33M$115.38M$186.48M
Current assets$4.64M$4.22M$8.02M$14.82M$55.46M$58.50M$101.20M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$900.00K$725.00K$2.09M$7.63M$11.08M$16.95M$18.25M
Total equity incl. NCI$9.08M$8.85M$11.29M$10.45M$48.25M$59.49M$97.73M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$1.00M$556.00K$0$96.00K$100.00K$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$508.00K$390.00K$1.20M$2.97M$1.83M$1.15M$3.23M

Cash flow

Korsana Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$3.31M-$4.33M-$21.24M-$40.61M-$36.52M-$72.49M-$102.22M
Capital expendituresUnavailableUnavailableUnavailable$0$7.00K$1.52M$6.89M
Investing cash flowUnavailable$0$10.40M$0$1.46M$18.00K-$6.72M
Financing cash flow$3.32M$0$5.02M$29.00K$30.78M$28.09M$211.57M
Net change in cash$8.00K-$4.34M-$5.81M-$40.58M-$4.27M-$44.39M$102.62M
Stock-based compensation$441.00K$625.00K$1.07M$6.25M$9.61M$14.99M$19.63M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$0$65.00K$472.00K$2.30M$2.70M

Derived

Korsana Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$36.52M-$74.01M-$109.10M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-239.8%-181.4%Unavailable-6242.4%-1400.2%-3539.4%-2774.3%
FCF marginUnavailableUnavailableUnavailableUnavailable-926.5%-3223.6%-2420.7%
SBC / revenue21.3%31.2%Unavailable2105.1%243.8%653.0%435.6%
Current ratio5.15x5.83x3.85x1.94x5.00x3.45x5.55x
Revenue YoY growth3.7%Unavailable-100.0%-92.5%71.7%-49.1%Unavailable
Net margin-170.1%-152.8%Unavailable-14841.1%-1310.2%-3388.6%-2729.3%
R&D / revenue46.2%14.3%Unavailable2013.1%954.7%2457.1%2110.9%
CapEx / revenueUnavailableUnavailableUnavailableUnavailable0.2%66.4%152.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CYCN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-K/A · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-05View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.